Hunter Syndrome

Overview

Plain-Language Overview

Hunter Syndrome is a rare genetic disorder that affects the body's ability to break down certain complex sugars called glycosaminoglycans. These sugars build up in various tissues and organs, leading to problems in the skeletal system, heart, lungs, and nervous system. The condition primarily affects boys and causes symptoms such as distinctive facial features, joint stiffness, and developmental delays. Over time, the buildup of these substances can cause serious health issues, including heart and breathing difficulties. Early diagnosis is important to understand the progression and manage symptoms.

Clinical Definition

Hunter Syndrome (mucopolysaccharidosis type II) is an X-linked recessive lysosomal storage disorder caused by a deficiency of the enzyme iduronate-2-sulfatase due to mutations in the IDS gene. This enzyme deficiency leads to accumulation of dermatan sulfate and heparan sulfate in lysosomes, resulting in progressive cellular and tissue damage. The disorder primarily affects males and manifests with coarse facial features, hepatosplenomegaly, joint contractures, and variable cognitive impairment. Cardiac involvement, including valvular disease, and respiratory complications are common and contribute to morbidity. The clinical spectrum ranges from severe neurodegenerative forms to attenuated phenotypes with primarily somatic symptoms. Diagnosis is critical for early intervention and genetic counseling.

Inciting Event

Inherited mutation in the IDS gene causing iduronate-2-sulfatase deficiency is the primary initiating event.
No environmental or infectious triggers are involved in disease onset.

Latency Period

Symptoms usually develop within the first 2 to 4 years of life after birth.
Progressive accumulation of GAGs leads to gradual symptom onset over several years.

Diagnostic Delay

Early symptoms such as recurrent respiratory infections and developmental delay are nonspecific and often misattributed to common pediatric illnesses.
Lack of awareness of Hunter syndrome among clinicians delays consideration of lysosomal storage disorders.
Overlap of clinical features with other mucopolysaccharidoses complicates early diagnosis.
Limited access to enzyme assay or genetic testing in some regions delays confirmation.

Clinical Presentation

Signs & Symptoms

Developmental delay and progressive cognitive decline
Recurrent respiratory infections due to airway obstruction and impaired clearance
Hearing loss and frequent otitis media
Coarse facial features and macroglossia
Hepatosplenomegaly and abdominal distension
Behavioral problems including hyperactivity and aggression

History of Present Illness

Progressive development of coarse facial features, including a broad nose and thick lips.
Onset of joint stiffness and restricted range of motion without significant inflammation.
Recurrent upper respiratory infections and otitis media are common early complaints.
Developmental delay and behavioral problems may appear in more severe phenotypes.
Hepatosplenomegaly and cardiac symptoms such as murmurs or heart failure signs develop over time.

Past Medical History

History of frequent respiratory infections and otitis media in early childhood.
Previous evaluations for developmental delay or growth abnormalities.
No prior enzyme replacement or hematopoietic stem cell therapy unless diagnosed earlier.

Family History

Affected male relatives with similar clinical features suggest X-linked inheritance.
Carrier status in female relatives may be identified through genetic testing.
Family history of unexplained early childhood death or progressive neurodegenerative disease may be present.

Physical Exam Findings

Coarse facial features including a broad nose, thick lips, and enlarged tongue
Hepatosplenomegaly due to glycosaminoglycan accumulation
Joint stiffness and limited range of motion without significant inflammation
Short stature and skeletal deformities such as dysostosis multiplex
Thickened skin and claw hand deformities

Diagnostic Workup

Diagnostic Criteria

Diagnosis of Hunter Syndrome is established by demonstrating deficient iduronate-2-sulfatase enzyme activity in leukocytes or fibroblasts. Elevated urinary glycosaminoglycans, specifically dermatan sulfate and heparan sulfate, support the diagnosis but are not definitive. Molecular genetic testing identifying pathogenic variants in the IDS gene confirms the diagnosis and allows for carrier detection. Clinical features such as characteristic facial dysmorphism, hepatosplenomegaly, and developmental delay guide suspicion before biochemical confirmation.

Pathophysiology

Key Mechanisms

Deficiency of the lysosomal enzyme iduronate-2-sulfatase due to mutations in the IDS gene leads to accumulation of glycosaminoglycans (GAGs) such as dermatan sulfate and heparan sulfate.
Intracellular buildup of GAGs causes progressive cellular dysfunction and tissue damage in multiple organ systems.
Accumulation of GAGs in connective tissue results in coarse facial features, joint stiffness, and organomegaly.
GAG deposition in the central nervous system leads to neurodegeneration and developmental delay in severe cases.
Cardiac involvement includes valvular thickening and cardiomyopathy due to GAG infiltration.

Involvement	Details
Organs	Heart involvement includes valvular thickening and cardiomyopathy leading to heart failure.
	Liver and spleen enlargement occur due to glycosaminoglycan storage in reticuloendothelial cells.
	Airways are obstructed by soft tissue thickening causing respiratory complications.
	Central nervous system involvement may cause developmental delay and cognitive impairment.
Tissues	Connective tissue is thickened and dysfunctional due to glycosaminoglycan accumulation causing joint stiffness and skin changes.
Tissues	Cartilage abnormalities contribute to skeletal deformities and joint contractures.
Cells	Macrophages accumulate glycosaminoglycans leading to cellular dysfunction in multiple tissues.
Cells	Fibroblasts contribute to extracellular matrix abnormalities due to storage of undegraded substrates.
Chemical Mediators	Glycosaminoglycans (GAGs) accumulate intracellularly causing lysosomal storage and tissue damage.
Chemical Mediators	Iduronate-2-sulfatase deficiency is the enzymatic defect responsible for substrate accumulation.

Treatments

Pharmacological Treatments

Idursulfase
- Mechanism:
  - Recombinant enzyme replacement therapy providing functional iduronate-2-sulfatase to degrade accumulated glycosaminoglycans.
- Side effects:
  - Infusion reactions
  - Fever
  - Headache
  - Hypersensitivity reactions
- Clinical role:
  - First-line

Non-pharmacological Treatments

Supportive respiratory care including airway clearance techniques to manage obstructive airway disease.
Physical and occupational therapy to improve joint mobility and reduce contractures.
Surgical interventions such as adenotonsillectomy for obstructive sleep apnea and cardiac valve repair as needed.
Regular cardiac and neurological monitoring to manage progressive organ involvement.

Prevention

Pharmacological Prevention

Enzyme replacement therapy (ERT) with recombinant iduronate-2-sulfatase to reduce glycosaminoglycan accumulation
Hematopoietic stem cell transplantation (HSCT) in select cases to slow disease progression
Prophylactic antibiotics to prevent respiratory infections
Symptomatic treatment with analgesics for joint pain

Non-pharmacological Prevention

Regular cardiac and respiratory monitoring to detect early complications
Physical therapy to maintain joint mobility and function
Hearing aids and speech therapy to address sensory deficits
Sleep studies and airway management to prevent obstructive sleep apnea complications
Genetic counseling for affected families

Outcome & Complications

Complications

Cardiac failure from progressive valvular disease
Airway obstruction leading to respiratory distress or sleep apnea
Neurological decline with loss of cognitive and motor function
Skeletal deformities causing chronic pain and disability
Recurrent infections increasing morbidity

Short-term Sequelae	Long-term Sequelae
Frequent upper respiratory infections causing acute illness Sleep disturbances from obstructive sleep apnea Joint pain and stiffness limiting mobility Hearing loss worsening with recurrent otitis media	Progressive intellectual disability and neurodegeneration Severe cardiac valvular disease requiring surgical intervention Chronic respiratory insufficiency from airway obstruction Severe skeletal abnormalities leading to disability Early mortality often in the second decade without treatment

Differential Diagnoses

Hunter Syndrome versus Hurler Syndrome

Hunter Syndrome	Hurler Syndrome
X-linked recessive inheritance	Autosomal recessive inheritance
Symptoms usually appear between 2 and 4 years of age	Symptoms typically present within the first year of life
Milder neurocognitive decline with longer survival into adolescence or adulthood	More severe neurodegeneration and earlier death, often by 10 years
Deficiency of iduronate-2-sulfatase enzyme activity	Deficiency of alpha-L-iduronidase enzyme activity

Hunter Syndrome versus Sanfilippo Syndrome (MPS III)

Hunter Syndrome	Sanfilippo Syndrome (MPS III)
Excretion of dermatan sulfate and heparan sulfate in urine	Excretion of heparan sulfate in urine
Moderate neurocognitive decline with prominent somatic features	Severe progressive neurodegeneration with minimal somatic involvement
Deficiency of iduronate-2-sulfatase enzyme	Deficiency of enzymes involved in heparan sulfate degradation (e.g., sulfamidase)

Hunter Syndrome versus Morquio Syndrome (MPS IV)

Hunter Syndrome	Morquio Syndrome (MPS IV)
Excretion of dermatan sulfate and heparan sulfate in urine	Excretion of keratan sulfate in urine
Mild to moderate intellectual disability with skeletal abnormalities	Severe skeletal dysplasia with normal intelligence
Deficiency of iduronate-2-sulfatase enzyme	Deficiency of N-acetylgalactosamine-6-sulfatase or beta-galactosidase

Hunter Syndrome versus Glycogen Storage Disease Type II (Pompe Disease)

Hunter Syndrome	Glycogen Storage Disease Type II (Pompe Disease)
Normal creatine kinase with glycosaminoglycan accumulation	Elevated creatine kinase and glycogen accumulation in lysosomes
Coarse facial features and organomegaly with mild muscle involvement	Progressive muscle weakness and cardiomyopathy without coarse facial features
Deficiency of iduronate-2-sulfatase enzyme	Deficiency of acid alpha-glucosidase enzyme

Hunter Syndrome versus Niemann-Pick Disease Type A

Hunter Syndrome	Niemann-Pick Disease Type A
Deficiency of iduronate-2-sulfatase with glycosaminoglycan accumulation	Deficiency of sphingomyelinase with sphingomyelin accumulation
Mild to moderate neurocognitive decline without cherry-red macula	Rapid neurodegeneration with cherry-red macula and hepatosplenomegaly
Low iduronate-2-sulfatase enzyme activity in leukocytes	Low sphingomyelinase enzyme activity in leukocytes